Artigo Acesso aberto Revisado por pares

Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID ‐19 pandemic in Italy

2021; Wiley; Volume: 34; Issue: 5 Linguagem: Inglês

10.1111/dth.15035

ISSN

1529-8019

Autores

Luca Stingeni, Katharina Hansel, Elettra Antonelli, Giacomo Dal Bello, Cataldo Patruno, Maddalena Napolitano, Gabriella Fabbrocini, Teresa Grieco, Giovanni Pellacani, Maria Concetta Fargnoli, Maria Esposito, Viviana Piras, Myriam Zucca, Giampiero Girolomoni,

Tópico(s)

Asthma and respiratory diseases

Resumo

Dupilumab showed significant improvement of adolescent atopic dermatitis (AD) signs and symptoms in clinical trials, with a good safety profile. Herein we report the real-word effectiveness and safety of dupilumab in adolescents with moderate to severe AD from January to October 2020, during the COVID-19 pandemic in Italy. All patients had a diagnosis of AD for a mean [SD] 12.8 [3.1] years. Baseline demographics, AD characteristics (EASI, cDLQI, NRS itch score, NRS sleep loss score) at baseline and week 16, and safety data were collected. Nineteen patients (52.6% men; mean [SD] age, 15.6 [1.4] years [range, 13-17 years]) were included in the analysis. All patients reached EASI-50 and 78.9% EASI-75, especially in those with EASI≥30 and BMI < 25 at baseline, with marked reduction for cDLQI (77.4%), NRS itch score (5.9 point), and NRS sleep loss score (87.5%). One patient contracted asymptomatic SARS-CoV-2 infection and 1 developed mild conjuntivitis, without stopping dupilumab. In this real-word experience the effectiveness of dupilumab was excellent and resulted higher than that observed in clinical trials, with a good safety profile during COVID-19 pandemic.

Referência(s)
Altmetric
PlumX